Clopidogrel resistance in ischemic stroke patients: current insights, risk factors, and the role of platelet function testing - a narrative review.
TL;DR
The prevalence and predictors of clopidogrel resistance among ischemic stroke patients are explored, its potential impact on recurrent ischemic stroke is identified, and insights for the development of personalized and precision treatment strategies for clopidogrel treatment in patients with ischemic stroke are offered.
Abstract
Clopidogrel, as an antiplatelet drug, is important for the treatment of the secondary prevention of ischemic stroke according to the latest guidelines on ischemic stroke management. However, some patients still fail to achieve a drug response and experience ischemic events despite taking clopidogrel, due to differences in the production of active metabolites attributable to specific factors. While platelet function testing play a crucial role in evaluating the efficacy of antiplatelet drugs, research on their application remains relatively limited in the ischemic stroke population; thus, it is necessary to clarify their role in guiding individualized treatment for patients with ischemic stroke. In this review, we synthesize the current state of research on clopidogrel resistance in patients with ischemic stroke, covering key aspects such as the pharmacological mechanisms and metabolism of clopidogrel, the risk factors associated with clopidogrel resistance, and the clinical application of platelet function testing in ischemic stroke. Our study aims to explore the prevalence and predictors of clopidogrel resistance among ischemic stroke patients, identify its potential impact on recurrent ischemic stroke, and thereby offer insights for the development of personalized and precision treatment strategies for clopidogrel treatment in these patients.